MEDA AB | 8,929 Euro | +0,058 +0,65 % | |
| WKN: 935166 ISIN: SE0000221723 Ticker-Symbol: M5E | Frankfurt | 17.05.13 | 08:06 Uhr |
Branche PharmaAktienmarkt Sonstige |
|
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 07.05. | Meda AB (publ) AGM bulletin | 43 | Business Wire | |
| Regulatory News: At the annual general meeting (AGM) on May 7, 2013, of Meda AB (publ)(STO:MEDAA), corporate ID 556427-2812, Box 906, SE-170 09 Solna, Sweden, declared a dividend... Mehr lesen zu: Meda AB (publ) AGM bulletin | ||||
| 07.05. | MEDA: Interim Report, January–March 2013 | 50 | Business Wire | |
| Regulatory News: MEDA AB (STO:MEDAA) First quarter Group net sales reached SEK 3,199 million (3,375) corresponding to unchanged organic growth[1] compared to previous... Mehr lesen zu: MEDA: Interim Report, January–March 2013 | ||||
| 07.05. | XFRA DIVIDEND INFORMATION - 08.05.2013 - 2 | 210 | Xetra Newsboard | |
| FOLGENDE WERTPAPIERE WERDEN AM 07.05.2013 CUM DIVIDENDE UND AM 08.05.2013
EX DIVIDENDE GEHANDELT.
THE PRE-DIVIDEND DAY OF THE FOLLOWING SHARES WILL BE 07.05.2013. THE
EX-DIVIDEND DAY WILL BE 08.05.2013.
... Mehr lesen zu: XFRA DIVIDEND INFORMATION - 08.05.2013 - 2 | ||||
| 07.05. | XETI DIVIDEND INFORMATION - 08.05.2013 - 1 | 321 | Xetra Newsboard | |
| FOLGENDE WERTPAPIERE WERDEN AM 07.05.2013 CUM DIVIDENDE UND AM 08.05.2013
EX DIVIDENDE GEHANDELT.
THE PRE-DIVIDEND DAY OF THE FOLLOWING SHARES WILL BE 07.05.2013. THE
EX-DIVIDEND DAY WILL BE 08.05.2013.
... Mehr lesen zu: XETI DIVIDEND INFORMATION - 08.05.2013 - 1 | ||||
| 29.04. | Meda Dymista now available on prescription in UK | 1 | Pharma Bus Review | |
| 24.04. | Juma, MEDA picked for financial innovation grant | 2 | bizjournals | |
| 03.04. | MEDA AB (publ) NOTICE OF ANNUAL GENERAL MEETING 2013 | 38 | Business Wire | |
| Regulatory News: Notice is hereby given that the Annual General Meeting (AGM) of Meda AB, corporate ID 556427-2812, will be held at 5.00 PM on Tuesday, May 7, 2013, at Meda's headquarters... Mehr lesen zu: MEDA AB (publ) NOTICE OF ANNUAL GENERAL MEETING 2013 | ||||
| 27.03. | MEDA: Nomination Committee's Proposal to Composition of the Board | 59 | Business Wire | |
| Regulatory News: The Nomination Committee of Meda AB (STO:MEDAA) proposes the election of Karen Sörensen as new board member. The committee also proposes the re-election of Peter... Mehr lesen zu: MEDA: Nomination Committee's Proposal to Composition of the Board | ||||
| 14.03. | Meda Pharma allergic rhinitis drug Dymista gets UK MHRA approval | 9 | Pharma Bus Review | |
| 01.03. | MEDA: Acnex Approved in Europe | 40 | Business Wire | |
| Regulatory News:
MEDA (STO:MEDAA):
Acnex has received registration approval in Europe via the decentralized
procedure. Acnex is a novel... Mehr lesen zu: MEDA: Acnex Approved in Europe | ||||
| 22.02. | Synthetic Biologics Reports that Flupirtine Sublicensee, Meda AB, to Initiate Phase II Fibromyalgia Clinical Trial in U.S. | 69 | PR Newswire | |
| ROCKVILLE, Md., Feb. 22, 2013 /PRNewswire/ --Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, announced today... Mehr lesen zu: Synthetic Biologics Reports that Flupirtine Sublicensee, Meda AB, to Initiate Phase II Fibromyalgia Clinical Trial in U.S. | ||||
| 19.02. | Meda AB (publ) – Year-end report, January - December 2012 | 55 | Business Wire | |
| Regulatory News:
Meda AB (STO:MEDAA):
Full year 2012
· Group net sales reached SEK 12,991 million (12,856). At fixed exchange... Mehr lesen zu: Meda AB (publ) – Year-end report, January - December 2012 | ||||
| 24.01. | MEDA: Dymista Approved in Europe | 221 | Business Wire | |
| Regulatory News:
MEDA AB (publ)(STO:MEDAA)
Dymista has received medical approval in Europe via the decentralized
registration procedure.... Mehr lesen zu: MEDA: Dymista Approved in Europe | ||||
| 10.12. | Meda purchases MidNite OTC sleep aid | 7 | Pharma Bus Review | |
| 07.12. | Meda acquires OTC product in the U.S. | 75 | Business Wire | |
| Regulatory News:
Meda (STO:MEDAA) has signed an agreement to acquire MidNite, an OTC
sleep-aid product. MidNite is well established in the U.S. and holds a... Mehr lesen zu: Meda acquires OTC product in the U.S. | ||||
| 09.11. | Meda AB (publ) – Interim report, January–September 2012 | 35 | Business Wire | |
| Regulatory News:
Meda AB (STO:MEDAA):
Group net sales reached SEK 9,796 million (9,400). At fixed currency
rates, sales increased... Mehr lesen zu: Meda AB (publ) – Interim report, January–September 2012 | ||||
| 15.10. | MEDA: Acquisition of Women's Health products completed | 68 | Business Wire | |
| Regulatory News:
On September 6th, 2012, Meda announced an acquisition of pharmaceutical
products within Women's Health from Jazz Pharmaceuticals. This
... Mehr lesen zu: MEDA: Acquisition of Women's Health products completed | ||||
| 15.10. | Jazz Pharmaceuticals Completes Sale of its Women's Health Business to Meda | 65 | PR Newswire | |
| DUBLIN, Oct. 15, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the closing of the sale of its women's health business to Meda (an international specialty pharmaceutical... Mehr lesen zu: Jazz Pharmaceuticals Completes Sale of its Women's Health Business to Meda | ||||
| 15.10. | MEDA: Nomination committee appointed | 34 | Business Wire | |
| Regulatory News:
As per specifications set at Meda's 2012 annual general meeting, a
nomination committee has been appointed. It consists of:
... Mehr lesen zu: MEDA: Nomination committee appointed | ||||
| 06.09. | Meda acquires Women's Health products in the U.S. | 39 | Business Wire | |
| Regulatory News:
· Meda acquires a portfolio of pharmaceutical products within Women's
Health from Jazz Pharmaceuticals
· Meda increases... Mehr lesen zu: Meda acquires Women's Health products in the U.S. | ||||
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| ALK-ABELLO | 54,25 | -0,52 % | ALK-Abelló: License application for ragweed allergy immunotherapy tablet accepted for review by FDA |
| GRIFOLS | 29,012 | -0,06 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 11.12.2012 - 1 |
| OMEGA PHARMA | - | - | Initiative und Zenith teilen sich europäischen Mediaetat von Omega Pharma |
| NOVO NORDISK | 133,00 | -0,17 % | Novo Nordisk and Paula Deen Announce Winners of the Seeing Diabetes in a New Light' Contest |
| H LUNDBECK | 14,915 | +1,46 % | Takeda And Lundbeck Present Results From Pivotal Phase 3 Clinical Trials With Vortioxetine, An Investigational Compound For Major Depressive Disorder |
